Compare Merck & Co., Inc. (MRK) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vanguard Value Index Fund ETF — how do they compare? Merck & Co., Inc. trades at $144.98 (market cap $351.28B), while Vanguard Value Index Fund ETF trades at $220.13 (market cap $262.40B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Merck & Co., Inc. pays a 2.39% dividend while Vanguard Value Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| MRK | VTV | |
|---|---|---|
Market Cap | $351.28B | $262.40B |
Volume | 7,969,665 | 3,293,281 |
Sector | Health | — |
52-Week High | $156.43 | $227.51 |
52-Week Low | $82.49 | $182.86 |
Typical Hold Time | 98 Days | 142 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
VTV trades at $219.97, up 0.81% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings but faces selling pressure from institutional indicators. Recent news highlights value stock outperformance in 2026, with VTV beating growth counterparts by significant margins. The fund offers a 2.3% dividend yield and low 0.03% expense ratio, attracting income-focused investors amid market rotation from growth to value strategies.
VTV presents a compelling value proposition with strong 2026 performance and institutional accumulation. However, technical weakness and long-term underperformance versus broad market indices pose risks. The ETF's low-cost structure and dividend yield support defensive positioning, but investors should weigh recent momentum against historical tracking error concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
